ACRSAclaris Therapeutics, Inc.
Pharmaceutical Preparations
- Revenue
- $8M
- 58% YoY
- Operating margin
- -975.9%
- 29% YoY
- EBITDA
- −$76M
- 46% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$8M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired158% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear10% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $7M | $30M | $31M | $19M | $8M | 58% |
| Operating income | −$90M | −$90M | −$97M | −$142M | −$76M | 46% |
| Net income | −$91M | −$87M | −$88M | −$132M | −$65M | 51% |
| Operating cash flow | −$52M | −$68M | −$78M | −$20M | −$47M | 135% |
| Capex | $308K | $605K | $1M | $121K | $111K | 8.3% |
| Stock-based comp | $14M | $15M | $21M | $11M | $12M | 14% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 19 | — |
| FY2024 | — | — | 16 | — |
| FY2023 | — | — | 7 | — |